BBK Worldwide^® Blog

Getting Decentralized Right

What Matters to Patients

In Part 2 of our two-part interview with Phil Kelly, we delve further into the patient perspective on decentralized clinical trials. We ask Phil Kelly to share his thoughts on patient needs, tools, technologies, and the patient experience.

If you are conducting a decentralized clinical trial or planning for one, this is a must-see segment, with valuable insight to leverage for success.

Getting Decentralized Right

What Matters to Patients

We know the industry is ready to embrace decentralized clinical trials. But what about patients? What do they think about decentralized clinical trials? What elements are important to them? And what should sponsors consider when designing such trials?

To dig deep, we spoke one-on-one with Phil Kelly, a bladder cancer patient and advocate. He shares his experience and insight in Part 1 of this two-part series on the patient perspective.

Each year members of the industry gather together at Dpharm — a conference which challenges attendees to question how we, as an industry, can disrupt clinical research to reduce the burden to patients and physicians. This year's event will be held virtually September 28-29 and will focuses on making innovation stick in a post-COVID world.

Create a Patient- and Site-Centric Environment for Decentralized Clinical Trials

Hear from the Experts! 

As decentralized clinical trials reshape the clinical research landscape, BBK Worldwide® Chief Innovation Officer Rob Laurens and Lead Concierge Alex Nicholl discuss efforts to help study sponsors embrace these trials with ease and confidence.